Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) saw a large drop in short interest in December. As of December 31st, there was short interest totalling 1,810,000 shares, a drop of 47.4% from the December 15th total of 3,440,000 shares. Based on an average daily volume of 3,970,000 shares, the short-interest ratio is presently 0.5 days. Currently, 2.3% of the company's stock are sold short.

Hedge Funds Weigh In On Chimerix

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Assenagon Asset Management S.A. lifted its stake in shares of Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock valued at $2,846,000 after acquiring an additional 496,823 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after purchasing an additional 138,098 shares during the last quarter. Valeo Financial Advisors LLC raised its position in Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 69,505 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in Chimerix during the 2nd quarter valued at approximately $137,000. 45.42% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Trading Up 1.8 %

Shares of NASDAQ CMRX traded up $0.06 during mid-day trading on Tuesday, hitting $3.37. The company had a trading volume of 2,358,627 shares, compared to its average volume of 1,593,403. The company has a market capitalization of $303.08 million, a price-to-earnings ratio of -3.59 and a beta of 0.36. Chimerix has a 1 year low of $0.75 and a 1 year high of $3.80. The stock's 50-day moving average price is $2.06 and its 200-day moving average price is $1.31.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Wedbush reissued an "outperform" rating and issued a $6.00 price target on shares of Chimerix in a report on Tuesday, December 10th. HC Wainwright reissued a "buy" rating and set a $11.00 target price on shares of Chimerix in a research report on Monday, December 30th.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.